JP2023512175A5 - - Google Patents
Info
- Publication number
- JP2023512175A5 JP2023512175A5 JP2022542952A JP2022542952A JP2023512175A5 JP 2023512175 A5 JP2023512175 A5 JP 2023512175A5 JP 2022542952 A JP2022542952 A JP 2022542952A JP 2022542952 A JP2022542952 A JP 2022542952A JP 2023512175 A5 JP2023512175 A5 JP 2023512175A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- salt
- cancer
- hydrogen
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20155161 | 2020-02-03 | ||
| EP20155161.1 | 2020-02-03 | ||
| PCT/EP2021/052263 WO2021156180A1 (en) | 2020-02-03 | 2021-02-01 | [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023512175A JP2023512175A (ja) | 2023-03-24 |
| JP2023512175A5 true JP2023512175A5 (enExample) | 2024-02-08 |
| JP7626774B2 JP7626774B2 (ja) | 2025-02-04 |
Family
ID=69467427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542952A Active JP7626774B2 (ja) | 2020-02-03 | 2021-02-01 | ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230131720A1 (enExample) |
| EP (1) | EP4100412A1 (enExample) |
| JP (1) | JP7626774B2 (enExample) |
| CN (1) | CN115052881B (enExample) |
| WO (1) | WO2021156180A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11608343B2 (en) * | 2020-04-24 | 2023-03-21 | Boehringer Ingelheim International Gmbh | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors |
| TW202214641A (zh) * | 2020-06-30 | 2022-04-16 | 美商艾瑞生藥股份有限公司 | Ｈｅｒ２突變抑制劑 |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| CR20230604A (es) | 2021-06-26 | 2024-02-19 | Array Biopharma Inc | Inhibidores de mutación de her2 |
| WO2023081637A1 (en) * | 2021-11-02 | 2023-05-11 | Enliven Therapeutics, Inc. | Fused tetracyclic quinazoline derivatives as inhibitors of erbb2 |
| CN114031619A (zh) * | 2021-12-17 | 2022-02-11 | 山东汇海医药化工有限公司 | 一种图卡替尼中间体的制备方法 |
| CN114621221B (zh) * | 2022-03-12 | 2022-10-11 | 陕西海辰风扬医药科技有限公司 | 妥卡替尼关键中间体及其制备方法 |
| CN118715216A (zh) | 2022-03-28 | 2024-09-27 | 江苏恒瑞医药股份有限公司 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
| CN117384162A (zh) * | 2022-05-17 | 2024-01-12 | 浙江文达医药科技有限公司 | 选择性her2抑制剂 |
| WO2024027695A1 (zh) * | 2022-08-04 | 2024-02-08 | 微境生物医药科技(上海)有限公司 | 作为her2抑制剂的化合物 |
| US20240132521A1 (en) | 2022-08-22 | 2024-04-25 | Iambic Therapeutics, Inc. | Compounds and methods for modulating her2 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AR132562A1 (es) * | 2023-05-01 | 2025-07-16 | Enliven Inc | Formas polimórficas de (e)-1-((10s)-4-((4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)-2-fluoro-5-metilfenil)amino)-7,8,10,11-tetrahidro-9h-6,10-metanopirimido[4,5:5,6]pirido[3,2-b][1,4,7]oxadiazonin-9-il)-4-(dimetilamino)but-2-en-1-ona |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| CN116903615A (zh) * | 2023-06-21 | 2023-10-20 | 江苏丽源医药有限公司 | 一种妥卡替尼及其中间体的制备方法 |
| AU2024319770A1 (en) | 2023-08-07 | 2026-02-19 | Cogent Biosciences, Inc. | Compounds for fgfr inhibition |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| CN121270563A (zh) * | 2024-07-01 | 2026-01-06 | 北京鞍石生物科技股份有限公司 | 稠环化合物及其制备方法和应用 |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19608588A1 (de) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| AP2004003058A0 (en) * | 2001-12-12 | 2004-06-30 | Pfizer Prod Inc | Quinazoline derivatives for the treatment of abnormal cell growth. |
| JP2007510708A (ja) * | 2003-11-06 | 2007-04-26 | ファイザー・プロダクツ・インク | 癌の治療における選択的ｅｒｂＢ２阻害剤／抗ｅｒｂＢ抗体の組合せ |
| ATE446294T1 (de) | 2005-11-15 | 2009-11-15 | Array Biopharma Inc | N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten |
| JP6468611B2 (ja) * | 2014-05-13 | 2019-02-13 | アリアド ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
| EP3778584A1 (en) | 2014-06-19 | 2021-02-17 | ARIAD Pharmaceuticals, Inc. | Production process of 2-chloro-4-heteroaryl-pyrimidine derivatives |
| EP3294712A4 (en) | 2015-05-13 | 2018-11-07 | ARIAD Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| WO2017148391A1 (zh) | 2016-03-01 | 2017-09-08 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
| CN111032655B (zh) * | 2017-08-31 | 2022-09-02 | 达纳-法伯癌症研究所股份有限公司 | Egfr和/或her2抑制剂和使用方法 |
| JP7333313B2 (ja) | 2017-09-01 | 2023-08-24 | シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド | 窒素含有複素環化合物、製造方法、中間体、組成物および使用 |
-
2021
- 2021-02-01 JP JP2022542952A patent/JP7626774B2/ja active Active
- 2021-02-01 CN CN202180012676.0A patent/CN115052881B/zh active Active
- 2021-02-01 EP EP21703191.3A patent/EP4100412A1/en active Pending
- 2021-02-01 US US17/759,890 patent/US20230131720A1/en not_active Abandoned
- 2021-02-01 WO PCT/EP2021/052263 patent/WO2021156180A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023512175A5 (enExample) | ||
| JP2023512174A5 (enExample) | ||
| JP2986546B2 (ja) | スマトリプタンを含有する組成物 | |
| KR101673731B1 (ko) | 벰루페닙 및 mdm2 억제제의, 증식성 질환 치료용 복합 요법 | |
| ES2743699T3 (es) | Forma de dosificación oral de ketamina | |
| EP3177311B1 (en) | Drug combinations of cabozantinib with proteasome inhibitor to treat multiple myeloma | |
| JP2021536453A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP2019533660A5 (enExample) | ||
| JP2025013684A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| JP2022532766A5 (enExample) | ||
| JP4852605B2 (ja) | 放射線治療増強剤 | |
| CN120713908A (zh) | 帕布昔利布在黏膜恶性黑色素瘤中的应用 | |
| EP2425830A1 (en) | Synergistic drug combination for the treatment of cancer | |
| JP2024520567A (ja) | 肺線維症の予防または治療用の薬学製剤 | |
| JP2023531930A5 (enExample) | ||
| KR20130078147A (ko) | 일정한 입도를 갖는 ４，５―디아릴―３（２ｈ）―퓨라논 유도체를 포함하는 약학 조성물 | |
| JP6937308B2 (ja) | キノリン誘導体またはその塩を含有する医薬組成物の製造方法 | |
| JP2022518288A5 (enExample) | ||
| CN113347975A (zh) | 用于治疗侵蚀性手骨关节炎的孟鲁司特 | |
| WO2009040373A2 (en) | Galenical formulations of aliskiren | |
| CN120187730A (zh) | Prc2抑制剂的物理形式 | |
| JP2010535212A (ja) | 改良されたカンデサルタンの製剤 | |
| JP2002504134A (ja) | 疼痛を治療するためのドラフラジン類似体の使用 | |
| JP2008517924A5 (enExample) |